Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Thursday, August 21, 2008

Biochemical individuality: an article by Dr Michael Murray ND

The phrase "one man's meat is another man's poison" perfectly sums up how an individual could potentially react to drugs or herbs or other external or internally produced metabolites. If someone is sub-normal in a certain detox/activation enzyme, they may react very badly to something supposedly good for them.

Dr Michael Murray ND is one of the most respected natural therapists. In this article, he explains how the likes of drugs should be 'tailor-made' for each individual, because our detoxification/activation enzymes often vary greatly. At the moment drugs are designed as if we will all have the same metabolizing capability. This article is of interest in particular because it focuses on the main family of the 'phase 1'/'nonsynthetic reaction' enzymes, the cytochrome P450 (CYP450) family of enzymes. The flavin mono-oxygenase family (of which there are currently 6 different types known) are another of the phase1/nonsynthetic enzymes, but the CYP450 enzymes are regarded as the heavy duty ones, especially CYP3A4.

http://www.doctormurray.com/newsletter/07-19-2006.htm

More will be written about these enzymes and the other main detoxification enzymes over the weeks, in an effort to help us all learn about them.

keywords:
cytochrome P450, CYP450, CYP3A4
induction, inhibition, substrate
phase1 (nonsynthetic), phase 2 (synthetic)

Quotes:

One of the major determinants of our nutrigenomic profile is a family of perhaps one hundred enzymes known as the cytochrome P450 enzymes. These enzymes play a critical role in detoxifying drugs, cancer-causing compounds, and hormones. Generally, each enzyme is designed to metabolize certain types of chemicals, but there is also a lot of overlap among the P450 family. This “back-up system” ensures that your liver is usually able to detoxify your body efficiently...

...The activity of and interplay between Phase I and Phase II reactions is probably the single most important factor that determines our biochemical individuality. Differences in the P450 enzymes can explain why some people can smoke without developing lung cancer and why certain individuals are more susceptible to the harmful effects of pesticides and other toxic chemicals...

...The study examined the association between heart attack incidence.1 Unlike other studies looking into this association the researchers also measured the activity of the liver enzyme that detoxifies caffeine - cytochrome P450 1A2 (CYP1A2). When the researchers divided the group according to whether they possessed a form of this enzyme that quickly metabolizes caffeine (CYP1A2*1A) or slowly metabolized caffeine (CYP1A2*1F) suddenly the picture on the impact of caffeine intake became very clear. As can be seen from Table 1, those with the rapid caffeine breakdown actually decrease their risk of a heart attack by drinking coffee, while slow caffeine metabolizers actually dramatically increase their risk! Drinking four cups a day of coffee was associated with a 17% decrease risk in fast metabolizers and a 260% increased risk in slow metabolizers...
random links:

nutrigenomics research
http://www.medicine.iupui.edu/flockhart/table.htm

0 comments:

Post a Comment